- Report
- September 2026
- 192 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 196 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- January 2026
- 185 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 82 Pages
Global
From €5316EUR$5,850USD£4,569GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- May 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- September 2026
- 200 Pages
Global
From €7260EUR$7,990USD£6,241GBP
- Report
- July 2026
- 160 Pages
Global
From €4316EUR$4,750USD£3,710GBP
- Report
- August 2023
- 145 Pages
Global
From €2862EUR$3,150USD£2,460GBP
- Report
- February 2024
- 150 Pages
Global
From €4316EUR$4,750USD£3,710GBP
- Report
- February 2024
- 70 Pages
Japan
From €4316EUR$4,750USD£3,710GBP
- Report
- February 2024
- 70 Pages
Italy
From €4316EUR$4,750USD£3,710GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4316EUR$4,750USD£3,710GBP
- Report
- February 2024
- 70 Pages
Asia Pacific
From €4316EUR$4,750USD£3,710GBP

Linagliptin is a drug used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the amount of insulin released by the pancreas. Linagliptin is used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. It is also used to reduce the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Linagliptin is part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat conditions such as diabetes, obesity, and thyroid disorders. These drugs are used to control blood sugar levels, reduce cholesterol, and regulate hormones.
Companies in the Linagliptin market include Boehringer Ingelheim, Merck, Novartis, and Eli Lilly. Show Less Read more